Evidence map›Paper›PMID 38186185›Full record

ArticleAnnals of clinical and translational neurology2024

Aβ38 and Aβ43 do not differentiate between Alzheimer's disease and cerebral amyloid angiopathy.

Justina Dargvainiene, Ulf Jensen-Kondering, Benjamin Bender, Daniela Berg, Norbert Brüggemann, Charlotte Flüh, Robert Markewitz, Alexander Neumann, Benjamin Röben, Christoph Röcken and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of clinical and translational neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Justina Dargvainiene *Institute of Clinical Chemistry, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany.ORCID 0009-0002-4114-3748
Ulf Jensen-Kondering *Department of Neuroradiology, University Medical Center Schleswig-Holstein, Campus Lübeck, Lübeck, Germany.ORCID 0000-0002-0860-4410
Benjamin BenderDepartment of Radiology, Diagnostical and Interventional Neuroradiology, University Hospital of Tübingen, Tübingen, Germany.
Daniela BergDepartment of Neurology, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel University (CAU), Kiel, Germany.
Norbert BrüggemannDepartment of Neurology, University Medical Center Schleswig-Holstein, Campus Lübeck, Lübeck, Germany.
Charlotte FlühDepartment of Neurosurgery, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel University (CAU), Kiel, Germany.
Robert MarkewitzInstitute of Clinical Chemistry, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany.
Alexander NeumannDepartment of Neuroradiology, University Medical Center Schleswig-Holstein, Campus Lübeck, Lübeck, Germany.
Benjamin RöbenDepartment of Neurodegeneration, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.ORCID 0000-0002-4905-8698
Christoph RöckenDepartment of Pathology, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel University (CAU), Kiel, Germany.
Georg RoylDepartment of Neurology, University Medical Center Schleswig-Holstein, Campus Lübeck, Lübeck, Germany.
Claudia SchulteDepartment of Neurodegeneration, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.
Klaus-Peter WandingerInstitute of Clinical Chemistry, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany.
Caroline WeilerDepartment of Neurology, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel University (CAU), Kiel, Germany.
Nils G Margraf *Department of Neurology, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel University (CAU), Kiel, Germany.ORCID 0000-0003-2197-1079
Gregor Kuhlenbäumer *Department of Neurology, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel University (CAU), Kiel, Germany.ORCID 0000-0002-3262-8113

Funding

Clinician Scientist Program of the Faculty of Medicine of the University of Tübingen #478-0-0
6 · The paper itself

Abstract

Differential diagnosis between Alzheimer's disease (AD) and cerebral amyloid angiopathy (CAA) using cerebrospinal fluid (CSF) biomarkers is challenging. A recent study suggested that the addition of Aβ38 and Aβ43 to a standard AD biomarker panel (Aβ40, Aβ42, t-tau, p-tau) to improve the differential diagnosis. We tested this hypothesis in an independent German cohort of CAA and AD patients and controls using the same analytical techniques. We found excellent discrimination between AD and controls and between CAA and controls, but not between AD and CAA. Adding Aβ38 and Aβ43 to the panel did not improve the discrimination between AD and CAA.

Indexed as

Alzheimer DiseaseCerebral Amyloid AngiopathyAmyloid beta-PeptidesBiomarkersHumansPeptide FragmentsAmyloid beta-PeptidesBiomarkersPeptide Fragments

Identifiers

PMID38186185
PMCPMC10963288

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.